A small change in a molecule can make a big difference in how it behaves in the human body. Researchers at the University of Vienna, CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences and the Medical University of Vienna have now developed a simple and versatile way to make so-called “aminocyclopropanes” – compounds based on tiny, triangular structures to fine-tune the properties of biologically active molecules and future drug candidates. Their new method, published in Angewandte Chemie (DOI: 10.1002/anie.8092854) not only circumvents several limitations of conventional approaches, but also makes it easier to harness these triangles.

A phase 3 randomized controlled trial involving 614 patients with acute ischemic stroke who did not receive reperfusion therapy found that oral edaravone (TTYP01) initiated within 24 hours of symptom onset and continued for 28 days significantly improved functional outcomes. At 90 days, 65.4% of patients in the treatment group achieved excellent functional recovery (mRS 0–1) compared with 47.1% in the placebo group (OR 2.12, 95% CI 1.53–2.94, P <0.001). No significant differences in safety events were observed between the two groups.

September 7–9 | Dubai

Dr. Alex Aliper, Co-Founder and President of Insilico Medicine, has been invited to attend the AIM Congress 2026 in Dubai from September 7 to 9.

September 8 | Macau, China   

Dr. Feng Ren, Co-CEO and Chief Scientific Officer of Insilico Medicine, has been invited to attend and speak at the Fortune Leaders Forum in Macao on September 8.

September 8–10 | Paris

Dr. Alex Zhavoronkov, Founder and CEO of Insilico Medicine, has been invited to speak at the Nature conference: Redefining Healthcare in the Age of AI in Paris on September 8 at 16:30.

September 8–11 | Oxford

Insilico Medicine has been invited to attend the 75th BSRA Annual Scientific Meeting (2026) at the University of Oxford from September 8 to 11.

As reproductive medicine evolves worldwide, traditional anonymity in sperm donation is giving way to a growing recognition of an individual's right to know their genetic origins. Hosted by Kumamoto University, this international hybrid symposium brings together leading experts from Germany, Australia, New Zealand, and Japan. Join multidisciplinary discussions on legal frameworks, ethical challenges, and support systems shaping the global shift toward donor identity disclosure. Free and open to the public with simultaneous interpretation.

In addition to shrinking and regrowing, shrew skulls change shape with the seasons.

A clinical trial for patients with chronic obstructive pulmonary disease (COPD) shows that laughter therapy can reduce breathing difficulties and is as effective as more traditional breathing exercises. The research is presented at the European Respiratory Society Congress in Barcelona, Spain. Researchers say laughter therapy offers an effective low-cost treatment that patients can practice at home without any equipment or specialist support, alongside their other treatment.